DSCAM-AS1 up-regulation in invasive ductal carcinoma of breast and assessment of its potential as a diagnostic biomarker

Abstract

BACKGROUND:The long non-coding RNA (lncRNA) DSCAM-AS1 has been demonstrated to participate in the pathogenesis of breast cancer and tamoxifen resistance. OBJECTIVE: To evaluate expression profile of DSCAM-AS1 in invasive ductal carcinoma of breast and its suitability as a biomarker for diagnosis of breast cancer. METHODS: We evaluated expression of DSCAM-AS1 in 108 breast tissues including tumoral and adjacent non-cancerous tissues (ANCTs) by means of quantitative real time PCR. RESULTS: DSCAM-AS1 was up-regulated in tumoral tissues compared with ANCTs (Fold change = 2.86, P = 0.011). Its expression was significantly higher in patients aged less than 55 compared with older patients (P = 0.02). However, its expression levels had not a good performance as a diagnostic biomarker for breast cancer. CONCLUSIONS: The significant up-regulation of DSCAM-AS1 in tumoral tissues compared with ANCTs provides further evidences for participation of this lncRNA in the pathogenesis of breast cancer.

WITHDRAWN: LncRNA DSCAM-AS1 Promotes Proliferation, Migration and Invasion of Colorectal Cancer Cells via Modulating miR-144-5p/CDKL1

“…The role of DSCAM-AS1 has also been investigated in several studies. It is con rmed that DSCAM-AS1 expression was upregulated in breast cancer [23]; DSCAM-AS1 can target miR-137 and EPS8 to facilitate the proliferation of breast cancer cells while arrest their apoptosis, and DSCAM-AS1 can enhance the drug resistance of tamoxifen [24]. The above researches uncovered that DSCAM-AS1 had the function as an oncogene.…”

LncRNA DSCAM-AS1 promotes colorectal cancer progression by acting as a molecular sponge of miR-384 to modulate AKT3 expression

“…In recent decades, evidence has highlighted that the dysregulation of lncRNAs on CRC could be a leading cause for tumor process [8,9]. Studies show that DSCAM-AS1 has a role in progression of several cancers, and that it can function as an oncogenic lncRNA in these cancers [10][11][12][13][14][15][16]. Although recently studies demonstrated that DSCAM-AS1 expression was upregulated and played a crucial role in CRC, the functional roles and underlying mechanism of DSCAM-AS1 in CRC cells remains largely unknown [17,18].…”

“…Many lncRNAs are verified to play tumor suppressor or oncogenic role in the progression of CRC [8,9], suggesting that lncRNAs could serve as a diagnosis marker and therapy agent. Down Syndrome Cell Adhesion Molecule (DSCAM) antisense (DSCAM-AS1), (DSCAM-AS1), a novel lncRNA, has been reported to be upregulated and function as oncogenic lncRNA in hepatocellular carcinoma [10], non-small lung cancer [11], ovarian cancer [12], melanoma [13] and breast cancer [14][15][16]. Despite recently studies demonstrated that DSCAM-AS1 expression was upregulated in CRC and was involved in CRC proliferation and invasion [17,18], the function and underlying mechanism of DSCAM-AS1 in CRC progression remains largely unknown.…”

Long Noncoding RNA DSCAM-AS1 Facilitates Colorectal Cancer Cell Proliferation and Migration via miR-137/Notch1 Axis

“…The identification of sensitive biomarkers for prognosis and diagnosis and novel therapeutic targets has a very essential clinical significance for the improvement of long-term survival of CRC. In recent years, growing evidence has suggested that lncRNAs are tightly linked to the initiation and development of human cancers [13,14,20,23]. Previous studies have suggested the vital role of DSCAM-AS1 in hepatocellular carcinoma [24], breast cancer [20] and ovarian cancer [15].…”